Breaking: India may start producing Sputnik V vaccine to defeat Covid-19, says Putin
Russian news agency TASS says Putin also proposed an increase in the pace of the creation of a vaccine research centre for BRICS countries Brazil, Russia, India, China and South Africa
- Nov 17, 2020,
- Updated Nov 17, 2020 6:42 PM IST
Russian President Vladimir Putin said on November 17 that India and China may start producing Russia's Sputnik V vaccine against COVID-19, according to RIA news agency. Russian news agency TASS reported that Putin also proposed an increase in the pace of the creation of a vaccine research centre for BRICS countries Brazil, Russia, India, China and South Africa.
Russia claimed that its Sputnik V vaccine is 92% effective at protecting people from COVID-19, according to interim trial results. This came after Pfizer said that its vaccine has an efficacy rate of more than 90 per cent.
Russia licenced its Sputnik-V COVID-19 vaccine for domestic use in August before it started large-scale trials. The first batch of Sputnik-5 is likely to reach Kanpur's Ganesh Shankar Vidyarthi Medical College by next week.
In September, Dr Reddy's and the Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, entered into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India. As part of the partnership, RDIF shall supply 100 million doses of the vaccine to Dr Reddy's upon regulatory approval in India.
Russian President Vladimir Putin said on November 17 that India and China may start producing Russia's Sputnik V vaccine against COVID-19, according to RIA news agency. Russian news agency TASS reported that Putin also proposed an increase in the pace of the creation of a vaccine research centre for BRICS countries Brazil, Russia, India, China and South Africa.
Russia claimed that its Sputnik V vaccine is 92% effective at protecting people from COVID-19, according to interim trial results. This came after Pfizer said that its vaccine has an efficacy rate of more than 90 per cent.
Russia licenced its Sputnik-V COVID-19 vaccine for domestic use in August before it started large-scale trials. The first batch of Sputnik-5 is likely to reach Kanpur's Ganesh Shankar Vidyarthi Medical College by next week.
In September, Dr Reddy's and the Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, entered into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India. As part of the partnership, RDIF shall supply 100 million doses of the vaccine to Dr Reddy's upon regulatory approval in India.